We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Teva Pharmaceutical Industries Ltd | NYSE:TEVA | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.06 | 0 | 01:00:00 |
By Maria Armental
Several medicines used to treat high-blood pressure and heart failure are being recalled in the U.S. over concerns they may be contaminated by a carcinogen.
The recall in the U.S. affects valsartan and valsartan/hydrochlorothiazide products from Teva Pharmaceutical Industries Ltd. (TEVA) and privately held Major Pharmaceuticals and Solco Healthcare, the Food and Drug Administration said Friday.
The FDA said it was looking into the recalled products' levels of N-nitrosodimethylamine, classified as a substance that could cause cancer, and assessing the possible effect on patients who had taking them.
The ingredient valsartan was supplied by a third party, the FDA said without identifying the supplier. Similar recalls last week, including in Europe and Canada, identified the supplier as China's Zhejiang Huahai Pharmaceutical Co. (600521.SH).
Solco on Friday said it would recall affected lots of the medications listed. Teva Pharmaceutical, Major Pharmaceuticals and Zhejiang Huahai couldn't be immediately reached for comment Friday.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
July 13, 2018 19:50 ET (23:50 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Teva Pharmaceutical Indu... Chart |
1 Month Teva Pharmaceutical Indu... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions